Analysis of antihyperglycemic drug prescriptions for patients with type 2 diabetes mellitus in the Arkhangelsk Region

Download full text PDF
DOI: https://doi.org/10.29296/25419218-2019-07-06
Issue: 
7
Year: 
2019

T.S. Orlova(1), O.V. Buyuklinskaya(1), E.E. Loskutova(2), I.V. Boiko(1), A.N. Plakuev(1) 1-North State Medical University, 51, Troitsky Prospect, Arkhangelsk 163000, Russian Federation; 2-Peoples’ Friendship University of Russia, 6, Miklukho-Maklai St., Moscow 117198, Russian Federation

Introduction. In modern society, the incidence of type 2 diabetes mellitus (DM-2) has reached pandemic levels. In 2017, a total of 425 million diabetic patients were registered; 90% of them were diagnosed with DM-2. Therefore, it is very relevant to analyze drug prescriptions for these patients and the possibility of their optimization for correcting the glycemic profile of patients with this disease. Objective: to analyze the prescriptions of antihyperglycemic agents used in the treatment of DM-2 at the regional level (in case of the Arkhangelsk Region) in conformity of drug prescriptions to the standard and algorithm for providing medical care to these patients. Material and methods. The investigation was performed using data from the federal registry of patients with diabetes mellitus. A sample included data on 16,218 patients aged 30 to 70 years who lived in the Arkhangelsk Region and were diagnosed with DM-2. Results. An analysis of the Federal Register data showed that DM-2 was twice more common in females than in males. There was a dramatic increase in the number of DM-2 patients over the age of 60 years. Conclusion. Evaluation of drug prescriptions revealed that monotherapy with antihyperglycemic drugs of the biguanide group was most commonly used.
Keywords: 
type 2 diabetes mellitus
prevalence
gender distribution
age composition
pharmacoepidemiological analysis
antihyperglycemic drugs
monotherapy
combined therapy
References: 
  1. Dedov I.I., Shestakova M.V., Vikulova O.K. Epidemiology of diabetes mellitus in Russian Federation: clinical and statistical report according to the federal diabetes registry. Sakharnyy diabet, 2017; 20 (1): 13–41. https://doi.org/14341/DM8664 (in Russian).
  2. Standarts of specialized diabete scare (ed. By Dedov I.I., Shestakova M.V., Mayorov A.Y.). Sakharnyy diabet, 2017; 20 (1S): 1–112. https://doi.org/10.14341/DM20151S (in Russian).
  3. Tazhieva A.E., Reznik V.L., Ivanov S.V., Grzybowski A.M. Prevalence of complications of type 2 diabetes mellitus and concomitant diseases in Alma-Аty city, Republic of Kazakhstan in 2012–2016. Ekologiya cheloveka, 2017; 10: 57–64 (in Russian).
  4. American Diabetes Association.Diagnosisand Classification of Diabetes Mellitus. Diabetes Care 34. Suppl 1 (2011): 62–9.
  5. Federal State Statistics Service.The size and composition of the population. [Electronicresource]. Access mode: http://arhangelskstat.gks.ru/wps/wcm/connect/rosstat_ts/arhangelskstat/ru/statistics/population/ (circulation date15 November, 2018) (in Russian).
  6. Dedov I.I., Shestakova M.V., Vikulova O.K., Zheleznyakova A.V., Isakov M.А. Diabetes mellitus in Russian Federation: prevalence, morbidity, mortality, parameters of glycaemic control and structure of glucose lowering therapy according to the Federal Diabetes Register, status 2017. Russian Association of Endocrinologists, 2018 Received: 24.05.2018. Accepted: 10.06.2018 (in Russian).
  7. Zinman B., SkylerJ. S., Riddle M.C., Ferrannini E. Diabetes Research and Care Through the Ages, Diabetes Care, Oct 2017; 40 (10) 1302–13.
  8. Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, 2015; 386, 743–800.
  9. RiddleM.C., Herman W.H.The Cost of Diabetes Care - An Elephant in the Room. Diabetes Care,2018; 41 (5): 929–32.
  10. Nikonova T.V. Modernalgorithm of treatment of type 2 diabetes mellitus. To whom and how to assign a combination of hypoglycemic agents. Consilium Medicum, 2008; 09: 25–30 (in Russian)